Evusheld: Preventing COVID-19 in High-Risk Patients
Learn about the practical role of this treatment option in preventing COVID-19 in high-risk patients.
COVID-19 vaccines have been foundational in reducing the number of infections and severe outcomes associated with SARS-CoV2 infections.
Unfortunately, a portion of individuals with immunocompromising conditions do not respond to these COVID-19 vaccines as well as healthy individuals. As public health measures (e.g., masking, physical distancing) are being removed across the country, patients with a lower immune response to vaccines are at elevated risk of infections and severe COVID-19 outcomes.
Tixagevimab/Cilgavimab is a monoclonal antibody treatment that has been approved to be used to prevent COVID-19 infections in patients who are unable to mount an adequate immune response to COVID-19 vaccinations.
This webinar recording reviews the practical role of this treatment option to prevent COVID-19 in high risk patients.
By the end of this course, you should be able to:
- Discuss the indications and recommendations for Tixagevimab/Cilgavimab in preventing COVID-19 in high-risk patients
- Identify potential candidates for Tixagevimab/Cilgavimab to prevent COVID-19 infections and severe outcomes
- Discuss the potential adverse effects and administration of Tixagevimab/Cilgavimab
- List potential roles for pharmacists in recommending Tixagevimab/Cilgavimab
This course is brought to you by an educational grant from AstraZeneca.
Course at a glance:
Who should take this course:
This learning activity may be of interest to both community & hospital pharmacists, those supporting heme-oncology, transplant, and immune-compromised patient groups.